Antibiotic discovery and drug development refers to the scientific process of identifying, designing, and producing new antimicrobial agents that can effectively combat bacterial infections, especially those resistant to existing drugs. It encompasses the discovery of novel compounds, preclinical research, clinical trials, and the optimization of drug delivery systems.
The rise of antimicrobial resistance (AMR) poses a global health threat, undermining decades of progress in treating infectious diseases. This session on Antibiotic Discovery and Drug Development focuses on innovative strategies and technologies that drive the identification and development of next-generation antibiotics.
Key areas covered in this session include:
- Natural product-based antibiotic discovery
- Synthetic and semi-synthetic approaches to drug design
- Genomics and AI in antibiotic lead identification
- Mechanisms of resistance and target validation
- Drug repurposing and combination therapies
- Challenges in clinical translation and regulatory pathways
This session aims to bring together academic researchers, pharmaceutical innovators, and policy experts to present and discuss groundbreaking work that could shape the future of infectious disease treatment.